Immunotherapy & Immuno-Oncology
Part of Healthcare - Oncology
 JNJ | Johnson & Johnson | $0.7t | $266.15 | +0.3% | 3.8M |
 ABBV | ABBVIE INC. | $462.5b | $262.55 | +0.3% | 2.9M |
 MRK | Merck & Co., Inc. | $375.8b | $144.00 | -0.7% | 5.1M |
 AZN | AstraZeneca PLC | $250.7b | $163.00 | -1.2% | 2.7M |
 AMGN | Amgen Inc | $239.4b | $376.73 | -1.5% | 1.9M |
 BMY | Bristol-Myers Squibb Co. | $138.2b | $63.75 | -0.8% | 5.8M |
 REGN | Regeneron Pharmaceuticals Inc | $86.8b | $777.50 | -2.5% | 390.4K |
 MRNA | Moderna, Inc. Common Stock | $59.4b | $144.00 | -2.0% | 6.7M |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | $28.4b | $58.50 | -1.0% | 2.1M |
 IBRX | ImmunityBio, Inc. Common Stock | $8.4b | $8.10 | -2.6% | 7.8M |
 ACLX | Arcellx, Inc. Common Stock | $6.7b | $115.06 | -0.0% | 16.1M |
 CGON | CG Oncology, Inc. Common stock | $6.6b | $72.55 | -1.6% | 937.6K |
 IOVA | Iovance Biotherapeutics, Inc. Common Stock | $3.9b | $9.39 | +1.3% | 10.1M |
 RCUS | Arcus Biosciences, Inc. | $3.8b | $24.48 | +1.0% | 1.6M |
 SLS | SELLAS Life Sciences Group, Inc. Common Stock | $2.8b | $11.28 | -3.7% | 4.9M |
 NKTR | Nektar Therapeutics | $2.6b | $66.72 | -2.7% | 729.0K |
 PGEN | Precigen, Inc. Common Stock | $2.6b | $7.01 | +2.2% | 2.3M |
 XNCR | Xencor, Inc. | $2.0b | $23.55 | -3.3% | 1.2M |
 SNDX | Syndax Pharmaceuticals, Inc. | $1.8b | $18.09 | -1.4% | 907.0K |
 INBX | Inhibrx Biosciences, Inc. Common Stock | $1.8b | $105.70 | -3.6% | 176.2K |
 BCAX | Bicara Therapeutics Inc. Common Stock | $1.6b | $22.70 | -2.2% | 515.0K |
 IMTX | Immatics N.V. Ordinary Shares | $1.4b | $8.61 | -0.1% | 327.1K |
 REPL | Replimune Group, Inc. | $1.4b | $13.00 | -0.6% | 1.9M |
 CGEM | Cullinan Therapeutics, Inc. Common Stock | $1.4b | $20.53 | +0.7% | 908.7K |
 OMER | Omeros Corporation | $1.4b | $17.05 | -1.6% | 1.4M |
 JANX | Janux Therapeutics, Inc. Common Stock | $1.2b | $16.45 | -4.9% | 828.4K |
 CRVS | Corvus Pharmaceuticals, Inc. | $1.2b | $12.79 | -1.1% | 1.2M |
 CADL | Candel Therapeutics, Inc. Common Stock | $1.0b | $11.06 | +4.3% | 913.7K |
 CTMX | CytomX Therapeutics, Inc. | $0.8b | $2.74 | -15.6% | 7.1M |
 AURA | Aura Biosciences, Inc. Common Stock | $0.8b | $6.94 | -0.9% | 596.8K |
 CBIO | Crescent Biopharma, Inc. Common Stock | $0.7b | $18.80 | -4.4% | 313.3K |
 CMPX | Compass Therapeutics, Inc. Common Stock | $437.6m | $1.87 | -5.6% | 2.1M |
 AGEN | Agenus Inc. | $364.1m | $7.13 | +0.5% | 583.0K |
 ALXO | ALX Oncology Holdings Inc. Common Stock | $287.6m | $1.90 | -1.8% | 692.3K |
 MGNX | MacroGenics, Inc. | $270.7m | $4.04 | -4.0% | 220.7K |
 CGEN | Compugen Ltd | $249.1m | $2.42 | -2.6% | 329.6K |
 GLSI | Greenwich LifeSciences, Inc. | $231.0m | $16.12 | -0.2% | 85.1K |
 CHRS | Coherus Oncology, Inc. Common Stock | $219.4m | $1.34 | -6.3% | 691.8K |
 CUE | Cue Biopharma, Inc. | $195.8m | $31.20 | +3.1% | 121.7K |
 INDP | Indaptus Therapeutics, Inc. Common Stock | $155.9m | $3.69 | +15.3% | 1.9M |
 HURA | TuHURA Biosciences, Inc. Common Stock | $133.2m | $2.07 | -0.5% | 127.6K |
 GNLX | Genelux Corporation Common Stock | $115.4m | $2.50 | -2.4% | 199.7K |
 ONCY | Oncolytics Biotech, Inc. Common Shares | $109.2m | $0.80 | -4.0% | 890.4K |
 ANIX | Anixa Biosciences, Inc. | $106.5m | $2.72 | -4.6% | 346.0K |
 MAIA | MAIA Biotechnology, Inc. | $83.3m | $1.34 | -2.9% | 1.2M |
 XBIT | XBiotech Inc | $67.1m | $2.19 | +1.2% | 18.2K |
 ELTX | Elicio Therapeutics, Inc. Common Stock | $67.0m | $1.99 | 0.0% | 292.6K |
 INMB | INmune Bio Inc. Common stock | $65.2m | $2.27 | -3.0% | 337.7K |
 XLO | Xilio Therapeutics, Inc. Common Stock | $59.4m | $8.99 | +0.7% | 17.2K |
 IBO | Impact BioMedical, Inc. | $52.8m | $0.53 | +9.3% | 119.7K |